Fertility drugs can affect the liver, but serious liver injury from these medications is rare. The most common route to liver problems during fertility treatment isn’t the drugs themselves acting as toxins. Instead, it’s a complication called ovarian hyperstimulation syndrome (OHSS), which can temporarily disrupt liver function in its more severe forms. That said, certain oral fertility medications do carry a small, direct risk worth understanding.
How Oral Fertility Medications Affect the Liver
The two most commonly prescribed oral fertility drugs, clomiphene citrate and letrozole, are both processed through the liver. Each carries a slightly different risk profile.
Clomiphene citrate (often sold as Clomid) has been linked to liver injury in a small number of cases. In one published report, a 31-year-old man treated with clomiphene for just five days developed reddish-brown urine and upper abdominal pain. His liver enzyme levels were significantly elevated, and he was diagnosed with both liver injury and gallbladder inflammation. His liver function returned to normal after stopping the medication. Cases like this are uncommon, but they demonstrate that clomiphene can, in rare instances, directly stress the liver.
Letrozole (Femara) appears to be gentler on the liver overall. Elevated liver enzymes occur in up to 1% of women taking it, and these elevations are typically mild, produce no symptoms, and resolve on their own without needing a dose change.
Injectable Fertility Drugs and the OHSS Connection
Injectable gonadotropins, the hormones used to stimulate the ovaries during IVF, tell a different story. These drugs are not considered direct causes of liver injury. In a U.S. study that tracked 899 cases of drug-induced liver injury over nearly a decade, not a single case was attributed to gonadotropins or to assisted reproductive techniques in general. The NIH’s LiverTox database rates gonadotropins as “unlikely causes of clinically apparent liver injury.”
The caveat is ovarian hyperstimulation syndrome. When the ovaries overrespond to injectable hormones, the body can develop OHSS, a condition where fluid leaks from blood vessels into the abdomen and other tissues. In severe OHSS, liver enzyme levels are elevated in 25% to 40% of patients. These elevations are usually mild to moderate and primarily show up in two specific markers (ALT and AST), with little change in other liver values.
The exact mechanism behind this liver involvement isn’t fully understood, but researchers have proposed several explanations: the surge of circulating sex hormones may directly affect liver cells, increased vascular permeability may damage hepatic tissue, and reduced blood flow to the liver during the circulatory dysfunction of severe OHSS may cause temporary oxygen deprivation. Liver biopsies in a handful of severe cases have confirmed structural changes in liver cells consistent with these theories.
How Progesterone Delivery Matters
Progesterone supplementation is a standard part of most fertility protocols, and how it’s delivered determines how much work your liver has to do. Oral progesterone passes through the liver first, where it’s rapidly broken down. Its half-life is roughly five minutes, meaning the liver metabolizes it almost immediately. This “first-pass” metabolism is the reason oral doses need to be higher, and it puts more processing burden on liver tissue.
Vaginal progesterone largely bypasses the liver, absorbing directly into uterine tissue with only a small fraction entering general circulation. Intramuscular injections also avoid significant first-pass liver metabolism. For patients with any concern about liver strain, these alternative delivery routes reduce hepatic exposure considerably.
Pre-Existing Liver Conditions and Fertility Treatment
If you already have liver disease, fertility treatment requires extra planning. Patients with autoimmune hepatitis are generally advised to delay conception until their liver disease has been well controlled on stable medication doses for at least a year. One reason is that a commonly used immunosuppressant for autoimmune hepatitis, mycophenolic acid, carries a high risk of miscarriage and birth defects, so a medication switch needs to happen before pregnancy is pursued.
For patients with cirrhosis, IVF is not automatically ruled out, but the risks are real. In one retrospective study, three out of six patients with cirrhosis who underwent IVF had successful live births. However, a quarter had unsuccessful attempts, and one patient with autoimmune-related cirrhosis experienced a dangerous worsening of her liver disease after starting IVF, forcing treatment to stop entirely.
Symptoms to Watch For
Liver problems during fertility treatment don’t always announce themselves with obvious signs. The earliest symptoms tend to be vague: general fatigue, a feeling of being unwell, and non-specific abdominal discomfort. More telling is pain in the right upper quadrant of the abdomen, just below the ribs on the right side. Dark or reddish-brown urine, yellowing of the skin or eyes, and persistent nausea can also signal that the liver is under stress.
These symptoms overlap with other common side effects of fertility drugs, which is part of what makes them easy to dismiss. If you develop right-sided upper abdominal pain during or shortly after a fertility treatment cycle, especially alongside dark urine, that combination warrants prompt attention. In most reported cases, liver enzyme levels return to normal once the offending medication is stopped or OHSS resolves, but catching the problem early prevents it from progressing.